Logo

RXST

RxSight, Inc.

RXST

RxSight, Inc. • NASDAQ
$11.42 ▼ -0.87% (-0.10)
Market Cap $469.55 M
52w High $46.77
52w Low $6.32
Dividend Yield 0%
P/E -12.98
Volume 209.71K
Outstanding Shares 41.12M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $30.34M ▼ $36.405M ▼ $-9.816M ▲ -32.353% ▲ $-0.24 ▲ $-8.948M ▲
Q2-2025 $33.637M ▼ $39.193M ▲ $-11.786M ▼ -35.039% ▼ $-0.29 ▼ $-10.964M ▼
Q1-2025 $37.895M ▼ $39.003M ▲ $-8.19M ▼ -21.612% ▼ $-0.2 ▼ $-7.381M ▼
Q4-2024 $40.214M ▼ $37.416M ▲ $-5.938M ▲ -14.766% ▼ $-0.15 ▲ $-5.398M ▼
Q3-2024 $45.408M $34.446M $-6.338M -13.958% $-0.16 $-5.179M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $227.516M ▲ $308.533M ▼ $32.563M ▲ $275.97M ▼
Q2-2025 $227.491M ▼ $309.009M ▼ $30.997M ▼ $278.012M ▼
Q1-2025 $229.341M ▼ $313.044M ▼ $33.728M ▼ $279.316M ▼
Q4-2024 $237.223M ▲ $318.563M ▲ $37.325M ▲ $281.238M ▲
Q3-2024 $237.12M $310.469M $33.208M $277.261M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.816M ▲ $-1.187M ▲ $-9.004M ▼ $-530K ▼ $-10.723M ▼ $-1.768M ▲
Q2-2025 $-11.786M ▼ $-4.376M ▲ $14.652M ▼ $2.065M ▲ $12.355M ▲ $-5.913M ▲
Q1-2025 $-8.19M ▼ $-8.832M ▼ $20.855M ▲ $-735K ▼ $11.294M ▲ $-9.407M ▼
Q4-2024 $-5.938M ▲ $-4.26M ▼ $1.32M ▲ $2.976M ▲ $-13.999K ▲ $-5.107M ▼
Q3-2024 $-6.338M $730K $-9.26M $798K $-7.725M $-373K

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
L D D
L D D
 $10.00M ▲$10.00M ▲$10.00M ▲$0 ▼
Service Warranty Service Contracts And Accessories
Service Warranty Service Contracts And Accessories
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily for several years as adoption of RxSight’s lens system grows, moving the company from a very small base toward a more meaningful commercial footprint. Gross margins have improved as scale builds, which is typical for a device company moving from early launch into broader use. Despite this progress, the business is still loss‑making. Operating and net losses remain consistent with a company investing heavily in sales, marketing, and clinical support to build out a new category in eye surgery. The encouraging sign is that losses do not appear to be accelerating relative to revenue, suggesting improving efficiency, but the path to sustained profitability is not yet proven.

Balance Sheet

Balance Sheet The balance sheet shows a young growth company that has been building its asset base and shareholder equity over time. Total assets and equity have increased meaningfully since the early days, reflecting capital raised from investors and continued investment into commercialization and infrastructure. Debt levels look modest relative to the overall size of the company, which reduces financial risk from leverage. However, the cash position, while adequate for now, is not large relative to ongoing losses, so the company’s runway and any future need to raise additional capital are important watch points.

Cash Flow

Cash Flow RxSight has been consistently using cash in its operations, which is normal for a company in this stage that is prioritizing growth over near‑term profits. Operating cash outflows and free cash outflows generally mirror the income statement losses, indicating that reported losses largely translate into real cash usage. Capital spending has been relatively light, so most cash consumption is tied to running and scaling the business rather than heavy manufacturing build‑outs. This means cash burn is strongly linked to how fast the company chooses to invest in salesforce expansion, physician education, and R&D. Until the business model reaches scale, continued negative cash flow is a key risk to monitor.

Competitive Edge

Competitive Edge RxSight sits in a niche but rapidly growing corner of the cataract surgery market, focused on premium, customizable intraocular lenses. Its Light Adjustable Lens system is meaningfully differentiated: it is currently the only lens that can be fine‑tuned after surgery, which addresses a real clinical problem and can lead to more precise vision outcomes. The company benefits from strong intellectual property, first‑mover status, and meaningful switching costs once a clinic has purchased and integrated the light delivery device. At the same time, it competes against very large, entrenched eye‑care companies with broad product portfolios and deep relationships with surgeons. So while its technology offers a clear edge in personalization, the company must continue to execute well on education, training, and evidence generation to defend and grow its position.

Innovation and R&D

Innovation and R&D Innovation is at the heart of RxSight’s story. The Light Adjustable Lens itself is a novel platform, and the company is layering on additional features such as extended depth‑of‑focus versions and added safety mechanisms like UV‑protective technology. This shows an intent to keep improving visual quality and usability rather than relying on a single, static product. The firm is also signaling a pipeline mindset: enhancements to the lens, upgrades to the light delivery system, and potential entry into new clinical indications and geographies. Continued R&D spending and clinical data generation will be crucial for maintaining its technological lead, especially as larger competitors watch this space and may try to respond with their own solutions.

Summary

RxSight is a fast‑growing medical device company built around a distinctly differentiated technology in cataract surgery: a lens that can be adjusted after it is implanted. Revenue has been scaling from a small base, and margins are heading in a healthier direction, but the company remains in an investment phase with ongoing operating losses and negative cash flow. The balance sheet is supported by rising equity and only modest debt, yet sustained cash burn means financing and capital access remain important considerations. Competitively, RxSight combines patented technology, first‑mover advantage, and high switching costs, but operates in the shadow of much larger eye‑care players, making execution and surgeon adoption critical. Overall, the story is that of an early‑stage, technology‑driven medtech business: strong product differentiation and a clear clinical value proposition, balanced by the usual risks of scaling, capital needs, and competition from well‑funded incumbents. How effectively the company converts its innovation and installed base into durable, profitable growth over the next several years will be the key factor to watch.

NEWS

November 20, 2025 · 4:05 PM UTC

RxSight, Inc. to Present at the Piper Sandler Healthcare Conference

Read more

November 5, 2025 · 4:05 PM UTC

RxSight, Inc. Reports Third Quarter 2025 Financial Results

Read more

October 22, 2025 · 4:05 PM UTC

RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

Read more

October 16, 2025 · 4:05 PM UTC

RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting

Read more

October 8, 2025 · 7:10 PM UTC

RXSIGHT ALERT: Bragar Eagel & Squire, P.C. is Investigating RxSight, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more